drugset / Trial / NCT05005507
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen (HBsAg) changes from baseline for the treatment regimens of 24 weeks of JNJ-73763989 + 24 weeks of nucleos(t)ide analog (NA) + 12 or 24 weeks of pegylated interferon alpha-2a (PegIFN-alpha-2a) (with immediate or delayed start of PegIFN-alpha-2a treatment).
Timeline
- Start
- 2021-11-03
- Primary completion
- 2021-12-29
- Completion
- 2021-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-73763989 | Small interfering RNA (siRNA) | — | Subcutaneous |
| Subject | PegIFN-alpha-2a | Protein / enzyme biologic | — | Subcutaneous |
| Background | ETV | Unknown | — | Oral |
| Background | TAF | Unknown | — | Oral |
| Background | Tenofovir disoproxil fumarate | Small molecule | — | Oral |